NCT03538301
Completed
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
ConditionsIdiopathic Pulmonary Fibrosis
Overview
- Phase
- Phase 2
- Intervention
- ND-L02-s0201 (Low Dose)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Sponsor
- Nitto Denko Corporation
- Enrollment
- 123
- Locations
- 33
- Primary Endpoint
- Number of Participants Discontinuing Study Treatment Due to TEAEs
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.
Detailed Description
All subjects were treated with ND-L02-s0201 or placebo for 24 weeks (a total of 12 doses). Subject's participation in the study was approximately 40 weeks including a Screening and Baseline period of up to 6 weeks, a treatment period of 24 weeks (including the 2 weeks after the last study treatment), and a follow-up period of 10 weeks after End-of-Treatment (EOT).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Forced vital capacity (FVC) ≥ 45% of predicted.
- •Diffusion capacity of the lung for carbon monoxide (DLco) corrected for hemoglobin ≥ 30% of predicted value
- •Ratio of forced expiratory volume in 1 second (FEV1) to FVC ≥ 0.70.
Exclusion Criteria
- •Best, acceptable FVC from separate screening spirometry that differ by ≥ 200 mL.
- •Respiratory exacerbation(s) or hospitalization for IPF exacerbation within 3 months before screening.
- •Anticipated to receive a lung transplant during the subject's participation in the study.
- •Active smoker or smoking cessation within 12 weeks before screening.
- •Malignancy within the last 5 years, with the exception of curable cancer that has received adequate treatment.
- •Evidence of any unstable or untreated, clinically significant disease or condition that, in the opinion of the Investigator, might confound the interpretation of the study or place the subject at increased risk.
- •Treatment with high dose corticosteroids, cytotoxic agents, unapproved IPF targeted therapy, and cytokine modulating agents within 8 weeks or 5 half-lives (whichever is longer) before screening
- •Participation in an investigational study with the last dose of investigational product occurring within 8 weeks or 5 half-lives (whichever is longer) before screening.
- •Pregnant or breastfeeding.
- •Medical history of infection with HIV, hepatitis B, or hepatitis C.
Arms & Interventions
Dose Level 1
ND-L02-s0201 45mg
Intervention: ND-L02-s0201 (Low Dose)
Dose Level 2
ND-L02-s0201 90mg
Intervention: ND-L02-s0201 (High Dose)
Outcomes
Primary Outcomes
Number of Participants Discontinuing Study Treatment Due to TEAEs
Time Frame: Change in the incidence and severity of adverse events related to study treatment from baseline to 24 weeks
The number of participants with TEAEs leading to discontinuation from the study treatment. The Safety Population (including all participants who received at least one dose of study treatment) is presented. TEAE = treatment-emergent adverse event
Secondary Outcomes
- Rate of Decline in FVC From Baseline to Week 24(Baseline to Week 24)
- Events of Deterioration of IPF Resulting in Lung Transplantation or Death and Rate of Deterioration of IPF Resulting in Lung Transplantation(Baseline to 12 weeks after end of study treatment)
- Percent Change in FVC From Baseline to Week 24(Baseline to Week 24)
- Summary of Study Treatment Response of FVC(Baseline to Visit 14 (Day 169))
- Quantitative Changes of Interstitial Lung Abnormalities as Measured by HRCT(Baseline to Week 24)
- Rate of Decline in ppFVC From Baseline to Week 24(Baseline to Week 24)
- Absolute and Relative Change in FVC (L) From Baseline to Week 24(Baseline to Week 24)
- Absolute and Relative Change in ppFVC (%) From Baseline to Week 24(Baseline to Week 24)
- Events of Hospitalization for Respiratory Ailments or Death(up to 12 weeks after the end of study treatment)
- Change in DLCO and DLCO Corrected for Hemoglobin From Baseline to Week 24(Baseline to Week 24)
- Qualitative Changes of Interstitial Lung Abnormalities as Measured by HRCT(Baseline to Visit 14 (Day 169))
- Total Events of Death Due to All Causes(up to 12 weeks after the end of study treatment)
- Percent Change in ppFVC From Baseline to Week 24(Baseline to Week 24)
- Summary of Study Treatment Response of ppFVC(Baseline to Visit 14 (Day 169))
- Events of IPF Exacerbation or Death and Rate of First IPF Exacerbation(Baseline to study completion, up to Day 239)
Study Sites (33)
Loading locations...
Similar Trials
Terminated
Phase 2
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary AspergillosisAllergic Bronchopulmonary AspergillosisNCT03960606Pulmatrix Inc.7
Recruiting
Phase 2
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFIdiopathic Pulmonary FibrosisNCT05389215Daewoong Pharmaceutical Co. LTD.102
Completed
Phase 2
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionNon-cystic Fibrosis BronchiectasisPseudomonas AeruginosaLung InfectionNCT05616221Armata Pharmaceuticals, Inc.48
Completed
Phase 2
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSAmyotrophic Lateral Sclerosis (ALS)NCT02017912Brainstorm-Cell Therapeutics48
Terminated
Phase 2
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose ToleranceCystic FibrosisNCT02955888Liminal BioSciences Ltd.11